6 completed, 2 recruiting, 1 terminated, 1 unknown. 5 Phase 4, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 5 | Completed 3, Terminated 1, Unknown 1 |
| Not applicable | 1 | Completed 1 |
Follow Vista Klinik: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Monitoring of Non-foveal, Non-vision Compromising Atrophic Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression Age-Related Macular Degeneration, Geographic Atrophy | Recruiting | Medical University of Vienna | 200 | 2025-04-11 | 2025-05-15 | |
| Personalised Monitoring of Early and Intermediate Age-related Macular Degeneration With Artificial Intelligence and Identification of Disease Progression Age-Related Macular Degeneration | Recruiting | Medical University of Vienna | 500 | 2025-02-25 | 2025-05-15 | |
| Intravitreal Faricimab in Diabetic Macular Edema With Limited Response to Aflibercept FARICIMAB 6 Mg in 0.05 mL INTRAVITREAL INJECTION, SOLUTION [VABYSMO] - Diabetic Macular Edema | Phase 4 | Unknown | Vista Klinik | 30 | 2022-11-01 | 2022-11-09 |
| Intravitreal Brolucizumab in Neovascular Age-related Macular Degeneration With Limited Response to Aflibercept Brolucizumab 6 mg solution for intravitreal injection - Neovascular Age-related Macular Degeneration | Phase 4 | Terminated | Vista Klinik | 16 | 2020-07-20 | 2021-12-29 |
| Correlation Between Visual Acuity Measurements, Quality of Life and Morphological Parameters in Wet AMD Patients no intervention - Macular Degeneration | Completed | Dr. med. Katja Hatz | 53 | 2017-02-24 | 2018-02-20 | |
| Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab aflibercept 2mg - Neovascular Age-related Macular Degeneration | Phase 4 | Completed | Vista Klinik | 33 | 2013-05-01 | 2018-10-16 |
| Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy cross-sectional observation - Insulin-Dependent Diabetes Mellitus 1 | Completed | Vista Klinik | 150 | 2012-09-01 | 2018-02-28 | |
| SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia Ranibizumab, Lucentis - Choroidal Neovascularization, Age Related Macular Degeneration | Phase 4 | Completed | Vista Klinik | 20 | 2011-06-01 | 2018-02-01 |
| Time Course of Activity Signs at SD-OCT High Frequency Intravitreal Ranibizumab Treatment in CNV Due to AMD Ranibizumab - Choroidal Neovascularization, Age Related Macular Degeneration | Phase 4 | Completed | Vista Klinik | 30 | 2010-12-01 | 2018-01-08 |
| Prevalence of DRP and DME Among Type 1 Diabetics Treated With Long-term Intensified Insulin Therapy cross-sectional observation - Insulin-Dependent Diabetes Mellitus 1 | Not applicable | Completed | Vista Klinik | 150 | 2010-08-01 | 2018-01-03 |
Macular Degeneration (5) · Choroidal Neovascularization (2) · Diabetes Mellitus, Type 1 (2) · Diabetic Retinopathy (2) · Geographic Atrophy (1)
Intravitreal Injections (3) · Observation (2) · Ranibizumab (2) · Solutions (2) · aflibercept (1) · brolucizumab (1) · faricimab (1)
Switzerland (8) · Austria (2) · France (2) · Slovenia (2) · Spain (2) · United Kingdom (2)
Christian Pruente, MD (3) · Katja Hatz, MD (3) · Katja Hatz, PD Dr. med (1)